CVT/Astellas To Submit Regadenoson In Mid-2007, Following Successful Phase III Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Selective adenosine receptor agonist could replace market leader Adenoscan as the myocardial perfusion imaging agent of choice, CVT says.